Top

Published in:

01-08-2010

Intracoronary Ultrasound for Optimizing Stent Implantation

Authors: Elias A. Sanidas, Gary S. Mintz, Akiko Maehara, So-Yeon Choi, George D. Dangas, Martin B. Leon, Jeffrey W. Moses, Gregg W. Stone

Published in: Current Cardiovascular Imaging Reports | Issue 4/2010

Abstract

From the bare metal stent era, studies have demonstrated improved procedural results and fewer complications when using intravascular ultrasound (IVUS) guidance, compared with angiography alone. In the drug-eluting stent (DES) era, predictors of DES restenosis and thrombosis such as under-expansion, incomplete stent apposition, and edge-related problems are readily detectable by IVUS. Pre-intervention and post-intervention IVUS measurements can help to achieve more adequate lesion coverage and the best possible stent expansion in order to eliminate the common predictors of DES failures and, perhaps, also result in reduced adverse clinical outcomes.

Fitzgerald PJ, Oshima A, Hayase M, et al.: Final Results of the Can Routine Ultrasound Influence Stent Expansion (CRUISE) Study. Circulation 2000, 102:523–530.PubMed

Oemrawsingh PV, Mintz GS, Schalij MJ, et al.: Intravascular Ultrasound Guidance Improves Angiographic and Clinical Outcome of Stent Implantation for Long Coronary Artery Stenoses: Final Results of a Randomized Comparison With Angiographic Guidance (TULIP Study). Circulation 2003, 107:62–67.CrossRefPubMed

Gil RJ, Pawlowski T, Dudek D, et al.: Comparison of angiographically guided direct stenting technique with direct stenting and optimal balloon angioplasty guided with intravascular ultrasound. The multicenter, randomized trial results. Am Heart J 2007, 154:669–675.CrossRefPubMed

Russo RJ, Silva PD, Teirstein PS, et al.: A Randomized Controlled Trial of Angiography versus Intravascular Ultrasound-Directed Bare-Metal Coronary Stent Placement (The AVID Trial). Circ Cardiovasc Interv 2009, 2:113–123.CrossRefPubMed

Mintz GS, Weissman NJ: Intravascular ultrasound in the drug-eluting stent era. J Am Coll Cardiol 2006, 48:421–429.CrossRefPubMed

Kimura T, Abe K, Shizuta S, et al.: Long-Term clinical and angiographic follow-up after coronary stent placement in native coronary arteries. Circulation 2002, 105:2986–2991.CrossRefPubMed

Park SW, Lee SW, Koo BK, et al.: Treatment of diffuse in-stent restenosis with drug-eluting stents vs. intracoronary beta-radiation therapy: INDEED Study. Int J Cardiol 2008, 131:70–77.CrossRefPubMed

Holmes DR, Teirstein P, Satler L, et al.: 3-Year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) Trial. J Am Coll Cardiol Interv 2008, 1:439–448.

Stone GW, Ellis SG, O’Shaughnessy CD, et al.: Paclitaxel-eluting stents vs. vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA 2006, 295:1253–1263.CrossRefPubMed

10.

Kalińczuk L, Demkow M, Mintz GS, et al.: Impact of different re-stenting strategies on expansion of a drug-eluting stent implanted to treat bare-metal stent restenosis. Am J Cardiol 2009, 104:531–537.CrossRefPubMed

11.

Sonoda S, Morino Y, Ako J, et al.; for the SIRIUS Investigators: Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation. J Am Coll Cardiol 2004, 43:1959–1963.CrossRefPubMed

12.

Hong MK, Mintz GS, Lee CW, et al.: Intravascular ultrasound predictors of angiographic restenosis after sirolimus-eluting stent implantation. Eur Heart J 2006, 27:1305–1310.CrossRefPubMed

13.

•• Doi H, Maehara A, Mintz GS, et al.: Impact of in-stent minimal lumen area at 9 months post-stent implantation on 3-year target lesion revascularization-free survival: a serial intravascular ultrasound analysis from the TAXUS IV, V, and VI Trials. Circ Cardiovasc Interv 2008, 1:111–118. This is a large meta-analysis of intermediate ISR lesions with long-term follow-up indicating the MLA cutoff that best predicts 3-year TLR-free survival.CrossRefPubMed

14.

Ohlmann P, Mintz GS, Kim SW, et al.: Intravascular ultrasound findings in patients with restenosis of sirolimus and paclitaxel-eluting stents. Int J Cardiol 2008, 125:11–15.CrossRefPubMed

15.

Rathore S, Terashima M, Katoh O, et al.: Predictors of angiographic restenosis after drug eluting stents in the coronary arteries: contemporary practice in real world patients. EuroIntervention 2009, 5:349–354.PubMed

16.

Sakurai R, Ako J, Morino Y, et al.: Predictors of edge stenosis following sirolimus-eluting stent deployment: a quantitative intravascular ultrasound analysis from the SIRIUS trial. Am J Cardiol 2005, 96:1251–1253.CrossRefPubMed

17.

Liu J, Maehara A, Mintz GS, et al.: An integrated TAXUS IV, V, and VI intravascular ultrasound analysis of the predictors of edge restenosis after bare metal or paclitaxel-eluting stents. Am J Cardiol 2009, 103:501–506.CrossRefPubMed

18.

•• Doi H, Maehara A, Mintz GS, et al.: Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials. J Am Coll Cardiol Interv 2009, 2:1269–1275. This is a large meta-analysis of post-PCI lesions with angiographic follow-up indicating the MSA cutoff that best predicts ISR.

19.

Fujii K, Carlier SG, Mintz GS, et al.: Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation. An intravascular ultrasound study. J Am Coll Cardiol 2005, 45:995–998.CrossRefPubMed

20.

Okabe T, Mintz GS, Buch AN, et al.: Intravascular ultrasound parameters associated with stent thrombosis after drug-eluting stent deployment. Am J Cardiol 2007, 100:615–620.CrossRefPubMed

21.

Liu X, Doi H, Maehara A, et al.: A volumetric intravascular ultrasound comparison of early drug-eluting stent thrombosis versus restenosis. J Am Coll Cardiol Interv 2009, 2:428–434.

22.

Opolski MP, Pracon R, Mintz GS, et al.: Relation of drug-eluting stent strut distribution to stent thrombosis in coronary arteries. Am J Cardiol 2009, 104:343–348.CrossRefPubMed

23.

Kim YS, Koo BK, Seo JB, et al.: The incidence and predictors of postprocedural incomplete stent apposition after angiographically successful drug-eluting stent implantation. Catheter Cardiovasc Interv 2009, 74:58–63.CrossRefPubMed

24.

Guo N, Maehara A, Mintz GS, et al.: Incidence, mechanisms, predictors and clinical impact of acute and late stent malapposition after primary intervention in patients with acute myocardial infarction: an intravascular ultrasound substudy of the HORIZONS-AMI Trial. Circulation 2010, In press.

25.

Feres F, Andrande P, Costa RA, et al.: Angiographic and intravascular ultrasound findings following implantation of the Endeavor zotarolimus-eluting stents in patients from the real-world clinical practice. EuroIntervention 2009, 5:355–362.PubMed

26.

Kimura M, Mintz GS, Carlier S, et al.: Outcome after acute incomplete sirolimus-eluting stent apposition as assessed by serial intravascular ultrasound. Am J Cardiol 2006, 98:436–442.CrossRefPubMed

27.

Sanchez-Recalde A, Moreno R, Barreales L, et al.: Risk of late-acquired incomplete stent apposition after drug-eluting stent versus bare-metal stent. A meta-analysis from 12 randomized trials. J Interv Cardiol 2008, 20:417–422.

28.

Hoffmann R, Morice MC, Moses JW, et al.: Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events: intravascular ultrasound analysis from the multicentre, randomised, RAVEL, E-SIRIUS and SIRIUS trials. Heart 2008, 94:253–254.CrossRef

29.

Hong MK, Mintz GS, Lee CW, et al.: Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation 2006, 113:414–419.CrossRefPubMed

30.

•• Hong MK, Mintz GS, Lee CW, et al.: Impact of late drug-eluting stent malapposition on 3-year clinical events. J Am Coll Cardiol 2007, 50:1515–1516. This study reports 3-year-term follow-up of patients after ISA was detected at 6 months.CrossRefPubMed

31.

•• Hassan A, Bergheanu S, Stijnen T, et al.: Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. Eur Heart J 2009 Jan 21 (Epub ahead of print). This is the largest meta-analysis relating DES to ISA and ISA to very late ST.

32.

•• Cook S, Wenaweser P, Togni M, et al.: Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007, 115:2426–2434. This study describes clinical and IVUS predictors of very late ST.CrossRefPubMed

33.

•• Cook S, Ladich E, Nakazawa G, et al.: Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 2009, 120:391–399. This study showed that very late DES thrombosis is associated with inflammation and vessel remodeling and that inflammation is correlated with the extent of stent ISA.CrossRefPubMed

34.

Alfonso F, Pérez-Vizcayno MJ, Ruiz M, et al.: Coronary aneurysms after drug-eluting stent implantation: clinical, angiographic, and intravascular ultrasound findings. J Am Coll Cardiol 2009, 53:2053–2056.CrossRefPubMed

35.

Roy P, Steinberg DH, Sushinsky SJ, et al.: The potential clinical utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention with drug-eluting stents. Eur Heart J 2008, 29:1851–1857.CrossRefPubMed

36.

Maluenda G, Lemesle G, Ben-Dor I, et al.: Impact of intravascular ultrasound guidance in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv 2010, 75:86–92.PubMed

37.

Park SJ, Kim YH, Park DW, et al.: Impact of intravascular ultrasound guidance on long-term mortality in stenting for unprotected left main coronary artery stenosis. Circ Cardiovasc Interv 2009, 2:167–177.CrossRefPubMed

38.

Costa J, Mintz GS, Carlier SG, et al.: Intravascular ultrasound assessment of drug-eluting stent expansion. Am Heart J 2007, 153:297–303.CrossRefPubMed

39.

Park SJ, Kim YH, Lee BK, et al.: Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. J Am Coll Cardiol 2005, 45:351–356.CrossRefPubMed

40.

Seung KB, Kim YH, Park DW, et al.: Effectiveness of sirolimus-eluting stent implantation for the treatment of ostial left anterior descending artery stenosis with intravascular ultrasound guidance. J Am Coll Cardiol 2005, 46:787–792.CrossRefPubMed

41.

Leon MB, Park SJ: Left main coronary interventions treatment considerations: Consensus Recommendations from the 1^st Left Main Summit 2007, Transcatheter Cardiovascular Therapeutics in 2007. http://www.tctmd.com/show.aspx?id=68140. Assessed April 17, 2010.

42.

Shimada Y, Honda Y, Hongo Y, et al.: Sirolimus-eluting stent implantation in small coronary arteries: predictors of long-term stent patency and neointimal hyperplasia [abstract]. Circulation 2005, 112: II736.

43.

Costa RA, Mintz GS, Carlier SG, et al.: Bifurcation coronary lesions treated with the “crush” technique: an intravascular ultrasound analysis. J Am Coll Cardiol 2005, 46:599–605.CrossRefPubMed

44.

Hahn JH, Song YB, Sang-Yup Lee SY, et al.: Serial intravascular ultrasound analysis of the main and side branches in bifurcation lesions treated with the T-stenting technique. J Am Coll Cardiol 2009, 54:110–117.CrossRefPubMed

45.

Iakovou I, Schmidt T, Bonizzoni E, et al.: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005, 293:2126–2130.CrossRefPubMed

46.

Lemos PA, Serruys PW, van Domburg RT, et al.: Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the “real world”: the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004, 109:190–195.CrossRefPubMed

Title: Intracoronary Ultrasound for Optimizing Stent Implantation
Authors: Elias A. Sanidas
Gary S. Mintz
Akiko Maehara
So-Yeon Choi
George D. Dangas
Martin B. Leon
Jeffrey W. Moses
Gregg W. Stone
Publication date: 01-08-2010
Publisher: Current Science Inc.
Published in: Current Cardiovascular Imaging Reports / Issue 4/2010
Print ISSN: 1941-9066
Electronic ISSN: 1941-9074
DOI: https://doi.org/10.1007/s12410-010-9029-5

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Intracoronary Ultrasound for Optimizing Stent Implantation

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

Intravascular Thermography for Assessing Vulnerable Plaques

Fractional Flow Reserve: A Practical Update

Clinical Trial Report: The Presence and Rupture of Vulnerable Plaques in the Peripheral Circulation

Angioscopic Detection of Vulnerable Coronary Plaques

Intracoronary Ultrasound in Assessing Efficacy of Cardiovascular Drugs

Emerging Molecular Targets for Intravascular Imaging of High-Risk Plaques

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page